2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole | 220941-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole
• 英文别名: 2-[[4-(6-chloropyridazin-3-yl)piperazin-1-yl]methyl]-5-fluoro-1H-indole
• CAS: 220941-59-3
• 化学式: C₁₇H₁₇ClFN₅
• 分子量: 345.807
• InChiKey: HAEDOALGQUCLFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
  申请人：Pfizer Inc.

  公开号：US20030100757A1

  公开（公告）日：2003-05-29

  A compound of the formula 1 wherein a, T, V, X, Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts.

  该化合物的公式为1，其中a、T、V、X、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8和R9如上所定义，其药学上可接受的盐和含有这种化合物或其盐的制药组合物。
• Dopamine D4 ligands for the treatment of novelty-seeking disorders
  申请人：——

  公开号：US20020049209A1

  公开（公告）日：2002-04-25

  The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或预防新奇寻求障碍，如病理性赌博、注意力缺陷多动障碍、物质成瘾、药物成瘾、酒精成瘾和性成瘾的方法。所使用的化合物是多巴胺D4受体配体或其药学上可接受的盐。
• 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine
  申请人：Pfizer Inc

  公开号：US20040198734A1

  公开（公告）日：2004-10-07

  A compound of the formula 1 wherein a, T, V, X, Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts.

  该化合物的化学式为1，其中a，T，V，X，Y，Z，R1，R2，R3，R4，R5，R6，R7，R8和R9的定义如上所述，其药学上可接受的盐和含有这种化合物或其盐的制药组合物。
• Dopamine D4 Ligands for the treatment of novelty-seeking disorders
  申请人：Pfizer Products Inc.

  公开号：EP1177792A2

  公开（公告）日：2002-02-06

  The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

  使用多巴胺 D4 受体配体制造用于治疗或预防寻求新奇障碍的药物，特别是病态赌博、多动障碍性注意力缺陷症、药物成瘾、吸毒成瘾、酗酒成瘾和性成瘾。
• FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2121630B1

  公开（公告）日：2012-08-01